OBR Daily Commentary

forumImage

Targeted Tx Fails 2 Tests in Metastatic Renal Cancer

(MedPage Today/The Gupta Guide) Dec 4, 2013 - A mammalian target of rapamycin (mTOR) inhibitor failed to improve outcomes in metastatic renal cell carcinoma (RCC) as compared with other therapeutic options, according to two randomized trials.

Read Article arrow

Robert A. Figlin, MD., FACP (Posted: December 05, 2013)

quotes

The reports today of the lack of benefit from two randomized trials in renal cancer highlight the need for additional approaches in this disease. We still have but two targets in RCCa that have led to multiple FDA approvals. Those targets are the VEGF and the mTOR pathways. Despite significant advances these trials demonstrate that the benefits from additional trials targeting these pathways either alone or in combinations are not demonstrating advantages for patients. It is time to move on. We are doing so with recent efforts targeting the cMET pathway as well as agents in pivotal trials targeting checkpoint inhibition. Continuing to understand the biology of this disease while developing novel therapeutics should remain our focus.

quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics Professo...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Steven Spielberg Family Chair in Hematology Oncology P...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...